Shared Genes Are Rewriting the Boundary Between Childhood and Adult Neurology
Large-scale exome sequencing has shifted neurodevelopmental disorders from a largely clinical description to a genetically stratified group of conditions with substantial overlap with later-onset movement phenotypes. In this review, the central message is straightforward: genes long associated with early developmental impairment can also drive progressive disorders that present years later as spastic paraplegia, dystonia, or cerebellar ataxia. The same molecular lesion can therefore appear first as delayed motor milestones, intellectual disability, or a static encephalopathy, then re-emerge in adolescence or adulthood as a movement disorder with a progressive course.
That pattern has immediate clinical consequences. A child labeled with cerebral palsy may actually carry a monogenic cause, and the review notes that up to 30% of such cases may have a genetic etiology. When the diagnostic frame stays too narrow, families lose access to recurrence counseling, syndrome-specific surveillance, and a clearer explanation for why symptoms evolve in ways that do not fit a purely perinatal injury model.
A Monogenic Cause Is Commoner Than Traditional Teaching Suggested
The review places strong emphasis on the growing proportion of neurodevelopmental cases that can now be traced to single-gene disorders. Hypothesis-free sequencing has made it possible to identify pathogenic variants in genes that would not have been suspected from the bedside phenotype alone. In practice, this means clinicians are increasingly confronting genetic disorders that cut across old subspecialty silos: pediatric neurology, movement disorders, neurogenetics, and rehabilitation medicine.
The enrichment of causal variants in genes already linked to adult-onset progressive movement disorders is especially important. Spastic paraplegias, dystonias, and cerebellar ataxias were repeatedly named as overlapping phenotypes, reinforcing a developmental-to-degenerative continuum rather than a strict early-versus-late dichotomy. A variant that disrupts neuronal development can leave a lifelong vulnerability in motor circuitry, and later demands on those same circuits may expose the deficit more dramatically.
Transcription, Axon Growth, and Synapses Form the Common Biological Core
Three biological pathways emerge repeatedly across the shared genetic landscape: transcriptional regulation, neuritogenesis, and synaptic function. Each is plausible on mechanistic grounds. Transcriptional regulators determine when and where neuronal programs are switched on; if they fail, the brain may never establish normal networks in the first place. Neuritogenesis governs axon extension and circuit wiring, so disruption at that stage can leave motor pathways incorrectly assembled. Synaptic genes, meanwhile, influence how efficiently neurons communicate after circuits are formed, making them relevant both to developmental delay and to later motor failure when reserve is exhausted.
The overlap matters because it explains why the same gene can present with different timing and severity. A pathogenic variant may produce early developmental abnormalities in one person and a delayed, progressive movement disorder in another, depending on residual protein function, modifying variants, and the developmental stage at which the affected pathway becomes rate-limiting. In clinical terms, the phenotype is not fixed at birth. It can unfold over time.
Movement Disorders Need a Broader Genetic Lens
For movement-disorder specialists, the review argues for a wider diagnostic net. Genes first identified in children with neurodevelopmental syndromes are now entering the differential diagnosis of adults with unexplained spasticity, dystonia, or ataxia. That does not mean every movement disorder should be sequenced indiscriminately, but it does mean the pretest probability of a monogenic diagnosis is higher than older teaching suggested, especially when developmental history, learning difficulties, or nonmotor neurologic features are present.
This shift also has value at the bedside when the phenotype looks “nonclassical.” A child with a diagnosis of cerebral palsy who later develops worsening spasticity or a mixed movement disorder should not automatically be assumed to have a nonprogressive condition. The possibility of an underlying genetic disorder becomes more relevant when the clinical course does not match an isolated perinatal insult. In the adult clinic, a patient with lifelong motor impairment and new dystonia may carry a variant in a gene traditionally linked to childhood neurodevelopmental disease.
Genetic Testing Is Moving From Confirmation to Reclassification
The review makes a strong case that expanding knowledge of NDD genes should change how genetic testing is used in movement disorders. Testing is no longer simply a way to confirm a suspected syndrome after the clinical picture is already obvious. It is becoming a tool for reclassification, especially in patients whose diagnosis has been anchored to a non-genetic label for years.
Strong diagnostic suspicion may not come from a single hallmark sign. It may come from the combination of early developmental delay, pyramidal signs, progressive motor impairment, cerebellar findings, or a family history that does not fit an acquired injury model. In those settings, gene panels, exome sequencing, and reanalysis of prior data can identify variants that alter both prognosis and family counseling. A molecular diagnosis can also prevent repeated investigations that add burden without improving care.
The Bedside Gaps Remain Real
Even with the rapid expansion of gene discovery, translation to routine care still lags behind discovery. Many variants remain difficult to interpret, and not every pathogenic finding leads to a targeted therapy. The review is careful not to overstate the current therapeutic payoff. Instead, it points to the value of better diagnostic precision, more coherent phenotyping, and more deliberate linkage between pediatric and adult neurology.
One practical challenge is classification. When a gene can produce both a developmental syndrome and a progressive movement disorder, age at presentation alone is not enough to define the disorder. Clinicians need to ask whether the phenotype reflects a static early injury, a neurodevelopmental genetic condition, or an inherited disorder that has simply not yet declared its full course. That distinction changes what gets tested, how results are interpreted, and what families are told to expect.
The review closes with a clear research agenda rather than a therapeutic triumph. Better genotype-phenotype mapping, larger datasets, and careful bedside correlation are still needed to turn shared molecular insight into routine diagnostic clarity. For now, the strongest clinical message is the simplest one: many disorders once split between pediatrics and movement neurology belong to the same genetic continuum, and the diagnostic process should reflect that reality.